Targeting the endocannabinod system to limit myocardial and cerebral ischemic and reperfusion injury

Current Pharmaceutical Biotechnology

Volumn 13, Issue 1, 2012, Pages 46-58

  Tuma, Ronald F ^a   Steffens, Sabine ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cannabinoid receptors; Endocannabinoids; Excitotoxicity; Fibrosis; Inflammation; Ischemia reperfusion injury; Remodeling

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ADENOSINE A2 RECEPTOR AGONIST; ALTEPLASE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BAY 387271; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DEXANABINOL; ENDOCANNABINOID; O 1966; PALMIDROL; RIMONABANT; UNCLASSIFIED DRUG; WIN 55212A;

BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAUSE OF DEATH; CORONARY ARTERY BLOOD FLOW; EX VIVO STUDY; EXCITOTOXICITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; MOLECULAR MECHANICS; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; REPERFUSION INJURY; REVIEW;

ANIMALS; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; ENDOCANNABINOIDS; HUMANS; MYOCARDIAL INFARCTION; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; REPERFUSION INJURY;

ANIMALIA;

EID: 84855857001     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112798868665     Document Type: Review

References (161)

1. Libby, P. Inflammation in atherosclerosis. Nature, 2002, 420, 868-874.
2. Lutgens, E.; van Suylen, R.J.; Faber, B.C.; Gijbels, M.J.; Eurlings, P.M.; Bijnens, A.P.; Cleutjens, K.B.; Heeneman, S.; Daemen, M.J. Atherosclerotic plaque rupture: local or systemic process? Arterioscler Thromb Vasc Biol., 2003, 23, 2123-2130.
3. Lange, R.A.; Hillis, L.D. Reperfusion therapy in acute myocardial infarction. N. Engl. J. Med., 2002, 346, 954-955.
4. Yellon, D.M.; Hausenloy, D.J. Myocardial reperfusion injury. N. Engl. J. Med., 2007, 357, 1121-1135.
5. Frangogiannis, N.G. Chemokines in ischemia and reperfusion. Thromb. Haemost., 2007, 97, 738-747.
6. Steffens, S.; Montecucco, F.; Mach, F. The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb. Haemost., 2009, 102, 240-247.
7. Vinten-Johansen, J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc. Res., 2004, 61, 481-497.
8. Zhao, Z.Q.; Corvera, J.S.; Halkos, M.E.; Kerendi, F.; Wang, N.P.; Guyton, R.A.; Vinten-Johansen, J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol., 2003, 285, H579-588.
9. Lecour, S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway? J. Mol. Cell Cardiol., 2009, 47, 32-40.
10. Boengler, K.; Hilfiker-Kleiner, D.; Drexler, H.; Heusch, G.; Schulz, R. The myocardial JAK/STAT pathway: from protection to failure, Pharmacol. Ther., 2008, 120, 172-185.
11. Murphy, E. Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. Circ. Res., 2004, 94, 7-16.
12. Heusch, G.; Boengler, K.; Schulz, R. Cardioprotection: nitric oxide, protein kinases, and mitochondria, Circulation, 2008, 118, 1915-1919.
13. Halestrap, A.P.; Clarke, S.J.; Javadov, S.A. Mitochondrial permeability transition pore opening during myocardial reperfusion--a target for cardioprotection. Cardiovasc. Res., 2004, 61, 372-385.
14. Sun, Y. Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc. Res., 2009, 81, 482-490.
15. Braunwald, E.; Pfeffer, M. A. Ventricular enlargement and remodeling following acute myocardial infarction: mechanisms and management. Am. J. Cardiol., 1991, 68, 1D-6D.
16. Donnan, G.A.; Fisher, M.; Macleod, M.; Davis, S.M. Stroke. Lancet, 2008, 371, 1612-1623.
17. Lakhan, S. E.; Kirchgessner, A.; Hofer, M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J. Transl. Med., 2009, 7, 97.
18. Broderick, J.P. Endovascular therapy for acute ischemic stroke. Stroke, 2009, 40, S103-106.
19. Muir, K.W.; Tyrrell, P.; Sattar, N.; Warburton, E. Inflammation and ischaemic stroke. Curr. Opin. Neurol., 2007, 20, 334-342.
20. Rodriguez-Yanez, M.; Castillo, J. Role of inflammatory markers in brain ischemia. Curr. Opin. Neurol., 2008, 21, 353-357.
21. Wang, Q.; Tang, X.N.; Yenari, M.A. The inflammatory response in stroke. J. Neuroimmunol., 2007, 184, 53-68.
22. Carmichael, S.T. Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx, 2005, 2, 396-409.
23. Lipton, P. Ischemic cell death in brain neurons. Physiol. Rev., 1999, 79, 1431-1568.
24. Jean, W.C.; Spellman, S.R.; Nussbaum, E.S.; Low, W.C. Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. Neurosurgery, 1998, 43, 1382-1396; discussion 1396-1387.
25. D'Ambrosio, A.L.; Pinsky, D.J.; Connolly, E.S. The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection. Mol. Med., 2001, 7, 367-382.
26. Wong, C.H.; Crack, P.J. Modulation of neuro-inflammation and vascular response by oxidative stress following cerebral ischemiareperfusion injury. Curr. Med. Chem., 2008, 15, 1-14.
27. Klein, T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol., 2005, 5, 400-411.
28. Di Marzo, V.; Petrosino, S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol., 2007, 18, 129-140.
29. Howlett, A.C. Cannabinoid receptor signaling. Handb. Exp. Pharmacol., 2005, 53-79.
30. Howlett, A.C.; Blume, L.C.; Dalton, G.D. CB(1) cannabinoid receptors and their associated proteins. Curr. Med. Chem., 17, 1382-1393.
31. Turu, G.; Hunyady, L. Signal transduction of the CB1 cannabinoid receptor. J. Mol. Endocrinol., 2010, 44, 75-85.
32. Pacher, P.; Steffens, S. The emerging role of the endocannabinoid system in cardiovascular disease. Semin. Immunopathol, 2009, 31, 63-77.
33. Van Sickle, M.D.; Duncan, M.; Kingsley, P.J.; Mouihate, A.; Urbani, P.; Mackie, K.; Stella, N.; Makriyannis, A.; Piomelli, D.; Davison, J.S.; Marnett, L.J.; Di Marzo, V.; Pittman, Q.J.; Patel, K.D.; Sharkey, K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science, 2005, 310, 329-332.
34. Di Marzo, V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol. Res., 2009, 60, 77-84.
35. Bisogno, T.; Ligresti, A.; Di Marzo, V. The endocannabinoid signalling system: biochemical aspects. Pharmacol. Biochem. Behav., 2005, 81, 224-238.
36. Di Marzo, V. Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug Discov., 2008, 7, 438-455.
37. Schmid, P.C.; Schwartz, K.D.; Smith, C.N.; Krebsbach, R.J.; Berdyshev, E.V.; Schmid, H.H. A sensitive endocannabinoid assay. The simultaneous analysis of N-acylethanolamines and 2-monoacylglycerols. Chem. Phys. Lipids., 2000, 104, 185-191.
38. Galiegue, S.; Mary, S.; Marchand, J.; Dussossoy, D.; Carriere, D.; Carayon, P.; Bouaboula, M.; Shire, D.; Le Fur, G.; Casellas, P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem., 1995, 232, 54-61.
39. Bouchard, J.F.; Lepicier, P.; Lamontagne, D. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci., 2003, 72, 1859-1870.
40. Lepicier, P.; Lagneux, C.; Sirois, M. G.; Lamontagne, D. Endothelial CB1-receptors limit infarct size through NO formation in rat isolated hearts. Life Sci., 2007, 81, 1373-1380.
41. Lagneux, C.; Lamontagne, D. Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br. J. Pharmacol., 2001, 132, 793-796.
42. Joyeux, M.; Arnaud, C.; Godin-Ribuot, D.; Demenge, P.; Lamontagne, D.; Ribuot, C. Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc. Res., 2002, 55, 619-625.
43. Lepicier, P.; Bouchard, J.F.; Lagneux, C.; Lamontagne, D. Endocannabinoids protect the rat isolated heart against ischaemia. Br. J. Pharmacol., 2003, 139, 805-815.
44. Underdown, N.J.; Hiley, C.R.; Ford, W.R. Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br. J. Pharmacol., 2005, 146, 809-816.
45. Wagner, J.A.; Abesser, M.; Harvey-White, J.; Ertl, G. 2-Arachidonylglycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts. J. Cardiovasc. Pharmacol., 2006, 47, 650-655.
46. Shmist, Y.A.; Goncharov, I.; Eichler, M.; Shneyvays, V.; Isaac, A.; Vogel, Z.; Shainberg, A. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. Mol. Cell Biochem., 2006, 283, 75-83.
47. Di Filippo, C.; Rossi, F.; Rossi, S.; D'Amico, M. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J. Leukoc Biol., 2004, 75, 453-459.
48. Montecucco, F.; Lenglet, S.; Braunersreuther, V.; Burger, F.; Pelli, G.; Bertolotto, M.; Mach, F.; Steffens, S. CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/ reperfusion. J. Mol. Cell Cardiol., 2009, 46, 612-620.
49. Hajrasouliha, A.R.; Tavakoli, S.; Ghasemi, M.; Jabehdar-Maralani, P.; Sadeghipour, H.; Ebrahimi, F.; Dehpour, A.R. Endogenous cannabinoids contribute to remote ischemic preconditioning via cannabinoid CB2 receptors in the rat heart. Eur. J. Pharmacol., 2008, 579, 246-252.
50. Lim, S.Y.; Davidson, S.M.; Yellon, D.M.; Smith, C.C. The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction. Basic Res. Cardiol., 2009, 104, 781-792.
51. Durst, R.; Danenberg, H.; Gallily, R.; Mechoulam, R.; Meir, K.; Grad, E.; Beeri, R.; Pugatsch, T.; Tarsish, E.; Lotan, C. Can nabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am. J. Physiol. Heart Circ. Physiol., 2007, 293, H3602-3607.
52. Ryberg, E.; Larsson, N.; Sjogren, S.; Hjorth, S.; Hermansson, N.O.; Leonova, J.; Elebring, T.; Nilsson, K.; Drmota, T.; Greasley, P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol., 2007, 152, 1092-1101.
53. Carrier, E.J.; Auchampach, J.A.; Hillard, C.J. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc. Natl. Acad Sci. U S A., 2006, 103, 7895-7900.
54. Hasko, G.; Linden, J.; Cronstein, B.; Pacher, P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov., 2008, 7, 759-770.
55. Xu, Z.; Mueller, R.A.; Park, S.S.; Boysen, P.G.; Cohen, M.V.; Downey, J.M. Cardioprotection with adenosine A2 receptor activation at reperfusion. J. Cardiovasc Pharmacol., 2005, 46, 794-802.
56. Wagner, J.A.; Varga, K.; Ellis, E.F.; Rzigalinski, B.A.; Martin, B.R.; Kunos, G. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature, 1997, 390, 518-521.
57. Varga, K.; Wagner, J.A.; Bridgen, D.T.; Kunos, G. Platelet-and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J., 1998, 12, 1035-1044.
58. Batkai, S.; Jarai, Z.; Wagner, J.A.; Goparaju, S.K.; Varga, K.; Liu, J.; Wang, L.; Mirshahi, F.; Khanolkar, A.D.; Makriyannis, A.; Urbaschek, R.; Garcia, N., Jr.; Sanyal, A.J.; Kunos, G. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat. Med., 2001, 7, 827-832.
59. Wagner, J.A.; Hu, K.; Bauersachs, J.; Karcher, J.; Wiesler, M.; Goparaju, S.K.; Kunos, G.; Ertl, G. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J. Am. Coll Cardiol., 2001, 38, 2048-2054.
60. Wagner, J.A.; Hu, K.; Karcher, J.; Bauersachs, J.; Schafer, A.; Laser, M.; Han, H.; Ertl, G. CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. Br. J. Pharmacol., 2003, 138, 1251-1258.
61. Batkai, S.; Mukhopadhyay, P.; Harvey-White, J.; Kechrid, R.; Pacher, P.; Kunos, G. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am. J. Physiol. Heart Circ. Physiol., 2007, 293, H1689-1695.
62. Gaskari, S.A.; Liu, H.; Moezi, L.; Li, Y.; Baik, S.K.; Lee, S.S. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br. J. Pharmacol., 2005, 146, 315-323.
63. Mukhopadhyay, P.; Batkai, S.; Rajesh, M.; Czifra, N.; Harvey-White, J.; Hasko, G.; Zsengeller, Z.; Gerard, N.P.; Liaudet, L.; Kunos, G.; Pacher, P. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J. Am. Coll Cardiol., 2007, 50, 528-536.
64. Mukhopadhyay, P.; Rajesh, M.; Batkai, S.; Patel, V.; Kashiwaya, Y.; Liaudet, L.; Evgenov, O. V.; Mackie, K.; Hasko, G.; Pacher, P. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc. Res., 2010, 85, 773-784.
65. Batkai, S.; Rajesh, M.; Mukhopadhyay, P.; Hasko, G.; Liaudet, L.; Cravatt, B.F.; Csiszar, A.; Ungvari, Z.; Pacher, P. Decreased agerelated cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. Am. J. Physiol. Heart Circ. Physiol., 2007, 293, H909-918.
66. Defer, N.; Wan, J.; Souktani, R.; Escoubet, B.; Perier, M.; Caramelle, P.; Manin, S.; Deveaux, V.; Bourin, M.C.; Zimmer, A.; Lotersztajn, S.; Pecker, F.; Pavoine, C. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J., 2009, 23, 2120-2130.
67. Weis, F.; Beiras-Fernandez, A.; Sodian, R.; Kaczmarek, I.; Reichart, B.; Beiras, A.; Schelling, G.; Kreth, S. Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure. J. Mol. Cell Cardiol., 2010, 48, 1187-1193.
68. Schmid, P.C.; Krebsbach, R.J.; Perry, S.R.; Dettmer, T.M.; Maasson, J.L.; Schmid, H.H. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett., 1995, 375, 117-120.
69. Patel, S.; Carrier, E.J.; Ho, W.S.; Rademacher, D.J.; Cunningham, S.; Reddy, D.S.; Falck, J.R.; Cravatt, B.F.; Hillard, C.J. The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. J. Lipid Res., 2005, 46, 342-349.
70. Felder, C.C.; Nielsen, A.; Briley, E.M.; Palkovits, M.; Priller, J.; Axelrod, J.; Nguyen, D.N.; Richardson, J.M.; Riggin, R.M.; Koppel, G.A.; Paul, S.M.; Becker, G.W. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett., 1996, 393, 231-235.
71. Kempe, K.; Hsu, F.F.; Bohrer, A.; Turk, J. Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue. J. Biol. Chem., 1996, 271, 17287-17295.
72. Sugiura, T.; Yoshinaga, N.; Waku, K. Rapid generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in rat brain after decapitation. Neurosci. Lett., 2001, 297, 175-178.
73. Hillard, C.J. Role of cannabinoids and endocannabinoids in cerebral ischemia. Curr. Pharm. Des., 2008, 14, 2347-2361.
74. Muthian, S.; Nithipatikom, K.; Campbell, W.B.; Hillard, C.J. Synthesis and characterization of a fluorescent substrate for the Narachidonoylethanolamine (anandamide) transmembrane carrier. J. Pharmacol. Exp. Ther., 2000, 293, 289-295.
75. Degn, M.; Lambertsen, K.L.; Petersen, G.; Meldgaard, M.; Artmann, A.; Clausen, B.H.; Hansen, S.H.; Finsen, B.; Hansen, H.S.; Lund, T.M. Changes in brain levels of N-acylethanolamines and 2-arachidonoylglycerol in focal cerebral ischemia in mice. J. Neurochem., 2007, 103, 1907-1916.
76. Schabitz, W.R.; Giuffrida, A.; Berger, C.; Aschoff, A.; Schwaninger, M.; Schwab, S.; Piomelli, D. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke, 2002, 33, 2112-2114.
77. Naccarato, M.; Pizzuti, D.; Petrosino, S.; Simonetto, M.; Ferigo, L.; Chiodo Grandi, F.; Pizzolato, G.; Di Marzo, V. Possible Anandamide and Palmitoylethanolamide involvement in human stroke. Lipids Health Dis., 9, 47.
78. Amantea, D.; Spagnuolo, P.; Bari, M.; Fezza, F.; Mazzei, C.; Tassorelli, C.; Morrone, L.A.; Corasaniti, M.T.; Maccarrone, M.; Bagetta, G. Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17beta-estradiol. FEBS J., 2007, 274, 4464-4775.
79. Jin, K.L.; Mao, X.O.; Goldsmith, P.C.; Greenberg, D.A. CB1 cannabinoid receptor induction in experimental stroke. Ann. Neurol., 2000, 48, 257-261.
80. Zhang, M.; Martin, B.R.; Adler, M.W.; Razdan, R.K.; Ganea, D.; Tuma, R.F. Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury. Neuroscience, 2008, 152, 753-760.
81. Ashton, J.C.; Rahman, R.M.; Nair, S.M.; Sutherland, B.A.; Glass, M.; Appleton, I. Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci. Lett., 2007, 412, 114-117.
82. Sommer, C.; Schomacher, M.; Berger, C.; Kuhnert, K.; Muller, H.D.; Schwab, S.; Schabitz, W.R. Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra. Acta Neuropathol., 2006, 112, 277-286.
83. Leker, R.R. Nicaraven Chugai. Curr. Opin. Investig. Drugs, 2003, 4, 83-90.
84. Dirnagl, U.; Iadecola, C.; Moskowitz, M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci., 1999, 22, 391-397.
85. Kermer, P.; Klocker, N.; Bahr, M. Neuronal death after brain injury. Models, mechanisms, and therapeutic strategies in vivo. Cell Tissue Res., 1999, 298, 383-395.
86. Mackie, K.; Hille, B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells, Proc. Natl. Acad Sci. U S A., 1992, 89, 3825-3829.
87. Shen, M.; Thayer, S.A. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol., 1998, 54, 459-462.
88. Shen, M.; Piser, T.M.; Seybold, V.S.; Thayer, S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci., 1996, 16, 4322-4334.
89. Nagayama, T.; Sinor, A.D.; Simon, R.P.; Chen, J.; Graham, S.H.; Jin, K.; Greenberg, D.A. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci., 1999, 19, 2987-2995.
90. Mauler, F.; Mittendorf, J.; Horvath, E.; De Vry, J. Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J. Pharmacol. Exp. Ther., 2002, 302, 359-368.
91. Braida, D.; Pozzi, M.; Sala, M. CP 55,940 protects against ischemia-induced electroencephalographic flattening and hyperlocomotion in Mongolian gerbils. Neurosci. Lett., 2000, 296, 69-72.
92. Parmentier-Batteur, S.; Jin, K.; Mao, X.O.; Xie, L.; Greenberg, D.A. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J. Neurosci., 2002, 22, 9771-9775.
93. Hampson, A.J.; Grimaldi, M.; Axelrod, J.; Wink, D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. U S A., 1998, 95, 8268-8273.
94. Sinor, A.D.; Irvin, S.M.; Greenberg, D.A. Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett., 2000, 278, 157-160.
95. Chen, Y.; Buck, J. Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J. Pharmacol. Exp. Ther., 2000, 293, 807-812.
96. Krieger, D.W.; Yenari, M.A. Therapeutic hypothermia for acute ischemic stroke: what do laboratory studies teach us? Stroke, 2004, 35, 1482-1489.
97. Hoesch, R.E.; Geocadin, R.G. Therapeutic hypothermia for global and focal ischemic brain injury--a cool way to improve neurologic outcomes. Neurologist, 2007, 13, 331-342.
98. Barone, F.C.; Feuerstein, G.Z.; White, R.F. Brain cooling during transient focal ischemia provides complete neuroprotection. Neuroscience & Biobehavioral Reviews, 1997, 21, 31-44.
99. Maier, C.M.; Ahern, K.; Cheng, M.L.; Lee, J.E.; Yenari, M.A.; Steinberg, G.K. Optimal depth and duration of mild hypothermia in a focal model of transient cerebral ischemia: effects on neurologic outcome, infarct size, apoptosis, and inflammation. Stroke, 1998, 29, 2171-2180.
100. Busto, R.; Globus, M.Y.; Dietrich, W.D.; Martinez, E.; Valdes, I.; Ginsberg, M.D. Effect of mild hypothermia on ischemia-induced release of neurotransmitters and free fatty acids in rat brain. Stroke, 1989, 20, 904-910.
101. Kader, A.; Frazzini, V.I.; Baker, C.J.; Solomon, R.A.; Trifiletti, R.R. Effect of mild hypothermia on nitric oxide synthesis during focal cerebral ischemia. Neurosurgery, 1994, 35, 272-277; discussion 277.
102. Karibe, H.; Chen, S.F.; Zarow, G.J.; Gafni, J.; Graham, S.H.; Chan, P.H.; Weinstein, P.R. Mild intraischemic hypothermia suppresses consumption of endogenous antioxidants after temporary focal ischemia in rats. Brain Res., 1994, 649, 12-18.
103. Toyoda, T.; Suzuki, S.; Kassell, N.F.; Lee, K.S. Intraischemic hypothermia attenuates neutrophil infiltration in the rat neocortex after focal ischemia-reperfusion injury. Neurosurgery, 1996, 39, 1200-1205.
104. Tohyama, Y.; Sako, K.; Yonemasu, Y. Hypothermia attenuates hyperglycolysis in the periphery of ischemic core in rat brain. Exp. Brain Res., 1998, 122, 333-338.
105. Compton, D.R.; Gold, L.H.; Ward, S.J.; Balster, R.L.; Martin, B.R. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther., 1992, 263, 1118-1126.
106. Haavik, C.O.; Hardman, H.F. Hypothermic action of delta 9-tetrahydrocannabinol, 11-hydroxy-delta 9-tetrahydrocannabinol and 11-hydroxy-delta 8-tetrahydrocannabinol in mice. Life Sci., 1973, 13, 1771-1778.
107. Haavik, C.O.; Hardman, H.F. Evaluation of the hypothermic action of tetrahydrocannabinols in mice and squirrel monkeys. J. Pharmacol Exp. Ther., 1973, 187, 568-574.
108. Hillard, C.J.; Manna, S.; Greenberg, M.J.; DiCamelli, R.; Ross, R.A.; Stevenson, L.A.; Murphy, V.; Pertwee, R.G.; Campbell, W.B. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). Journal of Pharmacology & Experimental Therapeutics, 1999, 289, 1427-1433.
109. Azad, S.C.; Marsicano, G.; Eberlein, I.; Putzke, J.; Zieglgansberger, W.; Spanagel, R.; Lutz, B. Differential role of the nitric oxide pathway on delta(9)-THC-induced central nervous system effects in the mouse. Eur. J. Neurosci., 2001, 13, 561-568.
110. Hayakawa, K.; Mishima, K.; Nozako, M.; Hazekawa, M.; Ogata, A.; Fujioka, M.; Harada, K.; Mishima, S.; Orito, K.; Egashira, N.; Iwasaki, K.; Fujiwara, M. Delta9-tetrahydrocannabinol (Delta9-THC) prevents cerebral infarction via hypothalamic-independent hypothermia. Life Sci., 2007, 80, 1466-1471.
111. Zhang, M.; Martin, B.R.; Adler, M.W.; Razdan, R.J.; Kong, W.; Ganea, D.; Tuma, R.F. Modulation of Cannabinoid Receptor Activation as a Neuroprotective Strategy for EAE and Stroke. J. Neuroimmune Pharmacol., 2009.
112. Berger, C.; Schmid, P.C.; Schabitz, W.R.; Wolf, M.; Schwab, S.; Schmid, H.H. Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J. Neurochem., 2004, 88, 1159-1167.
113. Muthian, S.; Rademacher, D.J.; Roelke, C.T.; Gross, G.J.; Hillard, C.J. Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience, 2004, 129, 743-750.
114. Felder, C.C.; Joyce, K.E.; Briley, E.M.; Glass, M.; Mackie, K.P.; Fahey, K.J.; Cullinan, G.J.; Hunden, D.C.; Johnson, D.W.; Chaney, M.O.; Koppel, G.A.; Brownstein, M. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther., 1998, 284, 291-297.
115. Pegorini, S.; Zani, A.; Braida, D.; Guerini-Rocco, C.; Sala, M. Vanilloid VR1 receptor is involved in rimonabant-induced neuroprotection. Br. J. Pharmacol., 2006, 147, 552-559.
116. Zhuang, S.; Kittler, J.; Grigorenko, E.V.; Kirby, M.T.; Sim, L.J.; Hampson, R.E.; Childers, S.R.; Deadwyler, S.A. Effects of longterm exposure to delta9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions. Brain Res. Mol. Brain Res., 1998, 62, 141-149.
117. Louw, D.F.; Yang, F.W.; Sutherland, G.R. The effect of delta-9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res., 2000, 857, 183-187.
118. Murikinati, S.; Juttler, E.; Keinert, T.; Ridder, D.A.; Muhammad, S.; Waibler, Z.; Ledent, C.; Zimmer, A.; Kalinke, U.; Schwaninger, M. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. Faseb J., 24, 788-798.
119. Abood, M.E.; Rizvi, G.; Sallapudi, N.; McAllister, S.D. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci. Lett., 2001, 309, 197-201.
120. Gilbert, G.L.; Kim, H.J.; Waataja, J.J.; Thayer, S.A. Delta9-tetrahydrocannabinol protects hippocampal neurons from excitotoxicity. Brain Res., 2007, 1128, 61-69.
121. Schlicker, E.; Kathmann, M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci., 2001, 22, 565-572.
122. van der Stelt, M.; Veldhuis, W.B.; Maccarrone, M.; Bar, P.R.; Nicolay, K.; Veldink, G.A.; Di Marzo, V.; Vliegenthart, J.F. Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol. Neurobiol., 2002, 26, 317-346.
123. Varma, N.; Carlson, G.C.; Ledent, C.; Alger, B.E. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J. Neurosci., 2001, 21, RC188.
124. Hajos, N.; Katona, I.; Naiem, S.S.; MacKie, K.; Ledent, C.; Mody, I.; Freund, T.F. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur. J. Neurosci., 2000, 12, 3239-3249.
125. Katona, I.; Sperlagh, B.; Sik, A.; Kafalvi, A.; Vizi, E.S.; Mackie, K.; Freund, T.F. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci., 1999, 19, 4544-4558.
126. Mehta, S.L.; Manhas, N.; Raghubir, R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res. Rev., 2007, 54, 34-66.
127. Dutka, A.J.; Hallenbeck, J.M.; Kochanek, P. A brief episode of severe arterial hypertension induces delayed deterioration of brain function and worsens blood flow after transient multifocal cerebral ischemia. Stroke, 1987, 18, 386-395.
128. Dutka, A.J.; Kochanek, P.; Hallenbeck, J.M.; Storey, J.R. Air embolism may cause unrecognized ischemia of the gray-white junction. Undersea0 Biomed Res., 1988, 15, 99-106.
129. Dutka, A.J.; Kochanek, P.M.; Hallenbeck, J.M. Influence of granulocytopenia on canine cerebral ischemia induced by air embolism. Stroke, 1989, 20, 390-395.
130. Hallenbeck, J.M.; Dutka, A.J.; Kochanek, P.M.; Siren, A.; Pezeshkpour, G.H.; Feuerstein, G. Stroke risk factors prepare rat brainstem tissues for modified local Shwartzman reaction. Stroke, 1988, 19, 863-869.
131. Hallenbeck, J.M.; Dutka, A.J.; Tanishima, T.; Kochanek, P.M.; Kumaroo, K.K.; Thompson, C.B.; Obrenovitch, T.P.; Contreras, T.J. Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period. Stroke, 1986, 17, 246-253.
132. Dawson, D.A.; Ruetzler, C.A.; Carlos, T.M.; Kochanek, P.M.; Hallenbeck, J.M. Polymorphonuclear leukocytes and microcirculatory perfusion in acute stroke in the SHR. Keio. J. Med., 1996, 45, 248-252; discussion 252-243.
133. Kochanek, P.M.; Dutka, A.J.; Hallenbeck, J.M. Indomethacin, prostacyclin, and heparin improve postischemic cerebral blood flow without affecting early postischemic granulocyte accumulation. Stroke, 1987, 18, 634-637.
134. Kochanek, P.M.; Dutka, A.J.; Kumaroo, K.K.; Hallenbeck, J.M. Platelet activating factor receptor blockade enhances recovery after multifocal brain ischemia. Life Sci., 1987, 41, 2639-2644.
135. Kochanek, P.M.; Dutka, A.J.; Kumaroo, K.K.; Hallenbeck, J.M. Effects of prostacyclin, indomethacin, and heparin on cerebral blood flow and platelet adhesion after multifocal ischemia of canine brain. Stroke, 1988, 19, 693-699.
136. Kochanek, P.M.; Hallenbeck, J.M. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke, 1992, 23, 1367-1379.
137. Kataoka, H.; Kim, S.W.; Plesnila, N. Leukocyte-endothelium interactions during permanent focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab., 2004, 24, 668-676.
138. Kishimoto, T.K.; Rothlein, R. Integrins, ICAMs, and selectins: role and regulation of adhesion molecules in neutrophil recruitment to inflammatory sites. Adv. Pharmacol., 1994, 25, 117-169.
139. Maier, C.M.; Hsieh, L.; Yu, F.; Bracci, P.; Chan, P.H. Matrix metalloproteinase-9 and myeloperoxidase expression: quantitative analysis by antigen immunohistochemistry in a model of transient focal cerebral ischemia. Stroke, 2004, 35, 1169-1174.
140. Jackson, S.J.; Diemel, L.T.; Pryce, G.; Baker, D. Cannabinoids and neuroprotection in CNS inflammatory disease. J. Neurol. Sci., 2005, 233, 21-25.
141. Ni, X.; Geller, E.B.; Eppihimer, M.J.; Eisenstein, T.K.; Adler, M.W.; Tuma, R.F. Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult. Scler., 2004, 10, 158-164.
142. Walter, L.; Stella, N. Cannabinoids and neuroinflammation. Br. J. Pharmacol., 2004, 141, 775-785.
143. Zhang, M.; Adler, M.W.; Abood, M.E.; Ganea, D.; Jallo, J.; Tuma, R.F. CB(2) receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury. Microvasc. Res., 2009.
144. Rajesh, M.; Mukhopadhyay, P.; Batkai, S.; Hasko, G.; Liaudet, L.; Huffman, J.W.; Csiszar, A.; Ungvari, Z.; Mackie, K.; Chatterjee, S.; Pacher, P. CB2-receptor stimulation attenuates TNF-alphainduced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am. J. Physiol. Heart Circ. Physiol., 2007, 293, H2210-2218.
145. Golech, S.A.; McCarron, R.M.; Chen, Y.; Bembry, J.; Lenz, F.; Mechoulam, R.; Shohami, E.; Spatz, M. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res. Mol. Brain Res., 2004, 132, 87-92.
146. Ghosh, S.; Preet, A.; Groopman, J.E.; Ganju, R.K. Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol. Immunol., 2006, 43, 2169-2179.
147. Rajesh, M.; Pan, H.; Mukhopadhyay, P.; Batkai, S.; Osei-Hyiaman, D.; Hasko, G.; Liaudet, L.; Gao, B.; Pacher, P. Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/ reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J. Leukoc. Biol., 2007, 82, 1382-1389.
148. Murikinati, S.; Juttler, E.; Keinert, T.; Ridder, D.A.; Muhammad, S.; Waibler, Z.; Ledent, C.; Zimmer, A.; Kalinke, U.; Schwaninger, M. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J., 2009.
149. Klein, T.W.; Newton, C.A.; Friedman, H. Cannabinoids and the immune system. Pain Res. Manag., 2001, 6, 95-101.
150. Berdyshev, E.V. Cannabinoid receptors and the regulation of immune response. Chem. Phys. Lipids, 2000, 108, 169-190.
151. Maresz, K.; Carrier, E.J.; Ponomarev, E.D.; Hillard, C.J.; Dittel, B.N. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J. Neurochem., 2005, 95, 437-445.
152. Nunez, E.; Benito, C.; Pazos, M.R.; Barbachano, A.; Fajardo, O.; Gonzalez, S.; Tolon, R.M.; Romero, J. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse, 2004, 53, 208-213.
153. Mabuchi, T.; Kitagawa, K.; Ohtsuki, T.; Kuwabara, K.; Yagita, Y.; Yanagihara, T.; Hori, M.; Matsumoto, M. Contribution of microglia/ macrophages to expansion of infarction and response of oligodendrocytes after focal cerebral ischemia in rats. Stroke, 2000, 31, 1735-1743.
154. Schilling, M.; Besselmann, M.; Muller, M.; Strecker, J.K.; Ringelstein, E.B.; Kiefer, R. Predominant phagocytic activity of resident microglia over hematogenous macrophages following transient focal cerebral ischemia: an investigation using green fluorescent protein transgenic bone marrow chimeric mice. Exp. Neurol., 2005, 196, 290-297.
155. Han, K.H.; Lim, S.; Ryu, J.; Lee, C.W.; Kim, Y.; Kang, J.H.; Kang, S.S.; Ahn, Y.K.; Park, C.S.; Kim, J.J. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc. Res., 2009, 84, 378-386.
156. Hillard, C.J. Endocannabinoids and vascular function. J. Pharmacol. Exp. Ther., 2000, 294, 27-32.
157. Gebremedhin, D.; Lange, A.R.; Campbell, W.B.; Hillard, C.J.; Harder, D.R. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am. J. Physiol., 1999, 276, H2085-2093.
158. Wagner, J.A.; Jarai, Z.; Batkai, S.; Kunos, G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur. J. Pharmacol., 2001, 423, 203-210.
159. Schomacher, M.; Muller, H.D.; Sommer, C. Short-term ischemia usually used for ischemic preconditioning down-regulates central cannabinoid receptors in the gerbil hippocampus. Acta. Neuropathol., 2006, 111, 8-14.
160. Su, B.; Dong, H.; Ma, R.; Zhang, X.; Ding, Q.; Xiong, L. Cannabinoid 1 receptor mediation of spinal cord ischemic tolerance induced by limb remote ischemia preconditioning in rats. J. Thorac. Cardiovasc. Surg., 2009, 138, 1409-1416.
161. Wang, Q.; Peng, Y.; Chen, S.; Gou, X.; Hu, B.; Du, J.; Lu, Y.; Xiong, L. Pretreatment with electroacupuncture induces rapid tolerance to focal cerebral ischemia through regulation of endocannabinoid system. Stroke, 2009, 40, 2157-2164.